Floatz Rating
B60/100
Confidence
Indicative
Sponsor
The Christie NHS Foundation Trust
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06470880CT.gov Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor Therapy | — | Not Yet Recruiting | — | — | — |
NCT05304546CT.gov Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma | — | Completed | — | — | — |
NCT05926960CT.gov A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma | — | Terminated | — | — | — |
NCT04074096CT.gov Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis | — | Active Not Recruiting | — | — | — |
NCT05270044CT.gov Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. | — | Active Not Recruiting | — | — | — |
NCT05260684CT.gov Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US | — | Completed | — | — | — |
NCT05767879CT.gov (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma | — | Unknown | — | — | — |
NCT05097378CT.gov Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma | — | Unknown | — | — | — |
NCT05003622CT.gov Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors | — | Completed | — | — | — |
NCT04221438CT.gov Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement | — | Terminated | — | — | — |
Show 16 more trialsShow fewer
NCT04655157CT.gov Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma | — | Terminated | — | — | — |
NCT04741997CT.gov Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma | — | Recruiting | — | — | — |
NCT04759846CT.gov Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma | — | Withdrawn | — | — | — |
NCT04657991CT.gov A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma | — | Active Not Recruiting | — | — | — |
NCT03878719CT.gov Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma | — | Terminated | — | — | — |
NCT04720768CT.gov Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE | — | Unknown | — | — | — |
NCT04045691CT.gov Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment | — | Recruiting | — | — | — |
NCT03235245CT.gov Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib | — | Active Not Recruiting | — | — | — |
NCT03563729CT.gov Melanoma Metastasized to the Brain and Steroids | — | Recruiting | — | — | — |
NCT02902042CT.gov Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma | — | Completed | — | — | — |
NCT02910700CT.gov Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma | — | Active Not Recruiting | — | — | — |
NCT02263898CT.gov Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations | — | Withdrawn | — | — | — |
NCT02159066CT.gov LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma | — | Completed | — | — | — |
NCT01820364CT.gov LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma | — | Terminated | — | — | — |
NCT01909453CT.gov Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma | — | Completed | — | — | — |
NCT01894672CT.gov BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Encorafenib (this asset) | The Christie NHS Foundation Trust | P3 | B · 60 |
| Gm-Csf | Ultimovacs ASA | P4 | BBB |
| Sargramostim | Mayo Clinic | P3 | BBB |
| Cediranib | M.D. Anderson Cancer Center | P3 | BBB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Cyclophosphamide | Primmune Therapeutics, Inc. | P4 | BB |
| Temsirolimus | University of Regensburg | P2 | BB |
| Tebentafusp | Immunocore Ltd | P3 | BB |
| Dacarbazine | Suzhou BlueHorse Therapeutics Co., Ltd. | P3 | BB |
+42 more in the Melanoma cohort
Other indications for Encorafenib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colon Carcinoma | — | P3 | BB · 68 |
| Colon Adenocarcinoma | — | P2/3 | BB · 67 |
| Colorectal Cancer | — | P2 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Encorafenib in Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/encorafenib-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →